CStone Pharmaceuticals
CSPHF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $407 | $464 | $481 | $244 |
| % Growth | -12.2% | -3.6% | 97.5% | – |
| Cost of Goods Sold | $167 | $160 | $203 | $107 |
| Gross Profit | $240 | $304 | $278 | $137 |
| % Margin | 59% | 65.6% | 57.8% | 56.2% |
| R&D Expenses | $135 | $528 | $614 | $1,305 |
| G&A Expenses | $33 | $49 | $63 | $109 |
| SG&A Expenses | $167 | $248 | $390 | $473 |
| Sales & Mktg Exp. | $134 | $199 | $327 | $364 |
| Other Operating Expenses | $30 | $108 | $186 | $188 |
| Operating Expenses | $332 | $884 | $1,191 | $1,966 |
| Operating Income | -$92 | -$580 | -$912 | -$1,829 |
| % Margin | -22.5% | -125% | -189.5% | -750.6% |
| Other Income/Exp. Net | $0 | $213 | $9 | -$91 |
| Pre-Tax Income | -$91 | -$367 | -$903 | -$1,920 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$91 | -$367 | -$903 | -$1,920 |
| % Margin | -22.4% | -79.2% | -187.5% | -787.8% |
| EPS | -0.072 | -0.29 | -0.77 | -1.65 |
| % Growth | 75.3% | 62.3% | 53.3% | – |
| EPS Diluted | -0.072 | -0.29 | -0.77 | -1.65 |
| Weighted Avg Shares Out | 1,276 | 1,263 | 1,172 | 1,164 |
| Weighted Avg Shares Out Dil | 1,276 | 1,263 | 1,173 | 1,165 |
| Supplemental Information | – | – | – | – |
| Interest Income | $13 | $25 | $10 | $10 |
| Interest Expense | $15 | $12 | $8 | $2 |
| Depreciation & Amortization | $50 | $58 | $45 | $23 |
| EBITDA | -$26 | -$297 | -$850 | -$1,895 |
| % Margin | -6.4% | -64.1% | -176.5% | -777.6% |